AstraZeneca Expands Clinical Trial Network in Philippines

MANILA, Philippines — Pharmaceutical giant AstraZeneca is expanding its clinical trial footprint in the Philippines by tapping the Ayala Group’s health-care arm to identify and prepare additional hospitals where it can conduct research and test potential new treatments. Under a new partnership, the British-Swedish drugmaker will work with AC Health and its Healthway Medical Network. AstraZeneca, a global player in drug and vaccine development, views the Philippines as a significant region for its clinical trials. The partnership with AC Health is expected to enable the company to leverage the country's healthcare infrastructure to conduct trials involving a broader patient demographic. This move also signifies a strengthening of international cooperation within the Philippine medical sector. With its substantial population and developing healthcare infrastructure, the Philippines presents an attractive location for clinical trials. AstraZeneca's latest venture suggests a deepening investment in the nation's healthcare system and a potential contribution to enhancing local medical research capabilities.